Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial
Adds background on data and disorder throughout
July 24 (Reuters) -Pfizer's PFE.N gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment, the company said on Wednesday.
The data takes Pfizer one step closer to securing U.S. regulatory approval for a second gene therapy to treat hemophilia.
Pfizer had received the Food and Drug Administration's nod for Beqvez as a one-time gene therapy for hemophilia B, a less common type of the disorder, in April.
If approved, Pfizer's hemophilia A gene therapy will compete with BioMarin Pharmaceutical's one-time treatment Roctavian, which was approved in the U.S. last year and is priced at $2.9 million.
Currently, the standard-of-care treatment for hemophilia A patients is to undergo routine replacement of the clotting protein called Factor VIII.
Pfizer said its gene therapy for hemophilia A not only met the main goal of showing non-inferiority compared to the Factor VIII replacement therapy in reducing the annual bleeding rate in patients, but also showed superiority to the current standard treatment.
Data from the 75-patient pool also showed that 84% of patients who were given Pfizer's gene therapy had Factor VIII levels above 5% at 15 months post-infusion, the company said.
The company will present additional data at upcoming medical meetings, it added. Pfizer is co-developing the hemophilia A gene therapy from with Sangamo Therapeutics SGMO.O, from whom it had licensed the therapy.
People with hemophilia have a fault in a gene that regulates production of proteins called clotting factors, leading to spontaneous as well as severe bleeding following injuries or surgery.
Hemophilia A affects about 25 in every 100,000 male births worldwide, according to data cited by Pfizer, with majority of them having a moderate to severe form of the disease for which the gene therapy was tested.
Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
